ITGR

Business Context and Reporting Period

Company: Wilson Greatbatch Technologies, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Wilson Greatbatch Technologies, Inc.)

Reporting Period: Quarter and nine months ended September 30, 2004.

Business Overview: The Company operates two segments: Implantable Medical Components (IMC), manufacturing batteries and components for pacemakers and defibrillators, and Electrochem Power Solutions (EPS), producing high-performance batteries for oil, gas, and aerospace markets. In March 2004, the Company acquired NanoGram Devices Corporation (NDC) to expand materials science capabilities.

Key Financial Metrics

Liquidity: Current ratio is 7.0:1. The Company maintains a $20 million unused credit line.

Material Changes vs. Prior Period

• Revenue Decline: Sales decreased 20% in Q3 and 8% year-to-date (YTD). The IMC segment drove the decline with a 24% drop in Q3 sales, primarily due to a 21% volume decrease and 3% price decrease. Approximately 84% of the IMC volume decline was attributed to one major Cardiac Rhythm Management (CRM) customer.
• Profitability Compression: Operating income fell 58% in Q3 and 26% YTD. Net income dropped 61% in Q3 and 23% YTD. Gross margin contracted 400 basis points in Q3 due to price reductions and lower production volumes spreading fixed costs.
• Expense Increases: Research, development, and engineering (RD&E) costs rose 12% YTD due to the inclusion of NDC development costs. Other operating expenses increased significantly YTD due to a $2.0 million patent acquisition charge and $0.8 million in severance costs from a 7% workforce reduction in Q2.
• Cash Flow: Operating cash flow declined to $23.9M YTD from $42.1M in the prior year, driven by increased inventory levels to meet customer safety stock requirements and the payment of accrued bonuses.

Guidance, Outlook, and Risks

• Capital Expenditures: Capital spending was $26.0M YTD, significantly higher than historical levels, driven by new manufacturing plants in New York and Mexico and ERP implementation. Management estimates an additional $20.0M to $25.0M in capital spending for the remainder of 2004.
• Outlook: Management anticipates continued price pressure on IMC products. The decline in sales to the major CRM customer is not expected to reverse immediately. New facilities in Alden, NY, and Tijuana, Mexico, are on schedule for completion in Q1 2005.
• Accounting Changes: The Company will adopt EITF Issue 04-8 in Q4 2004, requiring a retroactive restatement of diluted EPS for prior periods. This could result in additional dilution of up to 4.1 million shares, though the impact is currently anti-dilutive for Q3 2004.
• Risks: Key risks include dependence on a limited number of customers, pricing pressure, product obsolescence, and the successful integration of acquisitions. The Company is also subject to regulatory changes in the healthcare industry.

Investor Verification Checklist

• Customer Concentration: Verify the status of the relationship with the major CRM customer responsible for 84% of the Q3 volume decline and the likelihood of volume recovery.
• Capital Spending Execution: Monitor the completion timeline and cost overruns for the new manufacturing facilities in New York and Mexico, given the high capital expenditure run rate.
• EPS Restatement: Confirm the impact of the EITF 04-8 adoption on diluted earnings per share when the Q4 2004 report is filed.
• Inventory Levels: Assess whether the increased inventory levels ($33.3M vs $28.6M prior year) align with actual customer demand or represent potential obsolescence risk.
• Patent Acquisition Value: Evaluate the strategic return on the $2.0 million patent acquisition charge recorded in Q2 regarding wet tantalum capacitors.